Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicated that history of chronic obstructive pulmonary disease (OR = 2.59, 95% CI: 1.09, 6.15; P = 0.03), adenocarcinoma (OR = 2.28, 95% CI: 1.88, 2.77; P < 0.01), advanced tumour stage (TNM III-IV vs. I-II, OR = 2.38, 95% CI: 1.99, 2.86; P < 0.01), history of central venous catheter (OR = 1.95, 95% CI: 1.36, 2.78; P < 0.01), history of chemotherapy (OR = 2.32, 95% CI: 1.80, 2.99, P < 0.01), high levels of D-dimer (WMD = 4.31, 95% CI: 2.53, 6.10; P < 0.01) and carcinoembryonic antigen (WMD = 10.30, 95% CI: 9.95, 10.64; P < 0.01) and a low level of partial pressure of oxygen (WMD = -25.97, 95% CI: -31.31, -20.62; P < 0.01) were clinical features of LC patients with PE compared to those without PE.
|
31568496 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, patients with lung fibrosis, pancreatic cancer, uremia, chronic obstructive pulmonary disease, colon cancer, Alzheimer's disease, rectum cancer, and lung cancer had highest media levels of serum CEA in a descending order.
|
30905451 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined use of salivary biomarkers and carcinoembryonic antigen for lung cancer detection in a Chinese population.
|
31374012 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients.
|
30903516 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the new panel performed significantly better in lung cancer screening than did CEA and CA125 in all of the cohorts (<i>p</i>< .05).
|
31646071 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum CEA levels were quantified in each patient at the time of diagnosis of lung cancer.
|
31410309 |
2019 |
Malignant neoplasm of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.
|
31548657 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the predictive and prognostic roles of three blood-based biomarkers: circulating tumour DNA (ctDNA), circulating tumour cells (CTC) and carcinoembryonic antigen (CEA), in patients with advanced epidermal growth factor receptor-mutated (EGFR+) lung cancer.
|
31319980 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early detection of carcinoembryonic antigen (CEA) is of great significance for the screening, diagnosis, monitoring and prognosis analysis of lung cancer.
|
31072477 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effect of preoperative infusion chemotherapy combined with hyperthermia on sPD-L1 and CEA levels and overall survival of elderly patients undergoing radical resection of lung cancer.
|
31128008 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of long noncoding RNA <i>MALAT1</i> and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer.
|
29731641 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of CEA and CA125 in IPF patients were much higher in IPF patients with lung cancer (P ≤ .001).
|
29094803 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors built a model for lung cancer diagnosis previously based on the blood biomarkers progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1).
|
28940455 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate logistic regression model (LRM) identified tumor size, CEA, SCC, CYFRA21-1, pro-GRP, and HE4 as independent risk factors for lung cancer.
|
29412152 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detecting CTCs and tumor cells in BALF had similar areas under curves (AUC =0.871 and 0.963, respectively; P>0.05) in discriminating benign lesions from lung cancer (sensitivity 83.8% and 92.6%, specificity 86.5% and 99.9%, respectively), both of which were larger than those of NSE, CEA, and CA125 (AUC =0.564, 0.512 and 0.554, respectively; all P<0.05).
|
29780629 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significance of combined serum CEA and CA125 detection in lung cancer is confirmed.
|
30672447 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYFRA 21-1 sensitivity and specificity for lung cancer diagnosis was 37.3% and 90.9%, respectively, while that for CEA was 22.0% and 90.9%.
|
29970696 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the diagnostic efficiency of this marker for lung cancer using the combined analysis of carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), neuron specific enolase (NSE) and TK1.
|
29247745 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEA, PNI and p-stage are independent prognostic factors in elderly patients after surgery for primary lung cancer.
|
29528442 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
CEA in combination with LDCT significantly increases the value of lung cancer screening compared with using LDCT alone particularly in participants with indeterminate baseline LDCT in both initial and 2-year screening outcomes.
|
30032839 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The importance of our results was that we found decreased circulating HSP70, in combination with elevated CEA and CA 19-9, could be utilized in the diagnosis of early (stage I and II) lung cancer.
|
30245753 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CEA and hTERT in CTCs derived from the blood of a patient with lung cancer were also validated.
|
29435038 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum levels of SCC, Cyfra21-1, and CEA are markedly increased with increasing urinary albumin excretion, which affects the specificity for diagnosis for lung cancer.
|
28744310 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
About 37.5% of carcinoembryonic antigen (CEA)-negative lung cancer patients were CR-1 positive at 95% specificity.
|
26605871 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A classification rule based on EGF, sCD26, Calprotectin and CEA was established, able to reasonably discriminate lung cancer with 97% sensitivity and 43% specificity in the training set, and 91.7% sensitivity and 45.4% specificity in the validation set.
|
28117344 |
2017 |